Pradhan, D.; Jour, G.; Milton, D.; Vasudevaraja, V.; Tetzlaff, M.T.; Nagarajan, P.; Curry, J.L.; Ivan, D.; Long, L.; Ding, Y.;
et al. Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers 2019, 11, 2031.
https://doi.org/10.3390/cancers11122031
AMA Style
Pradhan D, Jour G, Milton D, Vasudevaraja V, Tetzlaff MT, Nagarajan P, Curry JL, Ivan D, Long L, Ding Y,
et al. Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers. 2019; 11(12):2031.
https://doi.org/10.3390/cancers11122031
Chicago/Turabian Style
Pradhan, Dinesh, George Jour, Denái Milton, Varshini Vasudevaraja, Michael T. Tetzlaff, Priyadharsini Nagarajan, Jonathan L. Curry, Doina Ivan, Lihong Long, Yingwen Ding,
and et al. 2019. "Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma" Cancers 11, no. 12: 2031.
https://doi.org/10.3390/cancers11122031
APA Style
Pradhan, D., Jour, G., Milton, D., Vasudevaraja, V., Tetzlaff, M. T., Nagarajan, P., Curry, J. L., Ivan, D., Long, L., Ding, Y., Ezhilarasan, R., Sulman, E. P., Diab, A., Hwu, W.-J., Prieto, V. G., Torres-Cabala, C. A., & Aung, P. P.
(2019). Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers, 11(12), 2031.
https://doi.org/10.3390/cancers11122031